Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis
1. The FDA has expanded the label for guselkumab (Tremfya) to include evidence that it can inhibit progression of structural ...
Tag: Guselkumab
Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with ...
Promising phase 2 results for new plaque psoriasis therapy
1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha ...
